Regeneron Pharmaceuticals (REGN) Stock Insights
REGN$951.19—
Market cap$95.23BEnterprise value—Revenue (TTM)$16.9BMarket positionTop 25%
Score
57
Neutral
Value
50
Quality
70
Growth
52
Insights
- Revenue by product
- Revenue by region
| Period | Value |
|---|---|
| FY2012 | Arcalyst Net Product Sales: 20200000.0, EYLEA Net Product Sales: 837900000.0 |
| FY2013 | Aflibercept Agreement: -15489000.0, Antibody Collaboration: 445600000.0 |
| FY2014 | Aflibercept Agreement: 5193000.0, Antibody Collaboration: 536106000.0 |
| FY2015 | Aflibercept Agreement: 15922000.0, Antibody Collaboration: 662990000.0, Immuno-oncology Agreement: 79961000.0, IO Agreement: 640000000.0 |
| FY2016 | Aflibercept Agreement: 26200000.0, Antibody Collaboration: 440168000.0, Immuno-oncology Agreement: 218497000.0, IO Agreement: 640000000.0 |
| FY2017 | Aflibercept Agreement: 24800000.0, Antibody Collaboration: 553689000.0, Immuno-oncology Agreement: 323504000.0 |
| FY2018 | Product: 4106200000.0 |
| FY2019 | Product: 4834400000.0 |
| FY2020 | Product: 5567600000.0 |
| FY2021 | Product: 12117200000.0, Product and Service, Other: 281200000.0 |
| FY2022 | Collaboration Revenue: 2058400000.0, Product: 6893700000.0, Product and Service, Other: 365100000.0 |
| FY2023 | Collaboration Revenue: 5503100000.0, Product: 7078000000.0, Product and Service, Other: 536100000.0 |
| FY2024 | Collaboration Revenue: 6057800000.0, Product: 7629200000.0, Product and Service, Other: 515000000.0 |
| FY2025 | Collaboration Revenue: 7331200000.0, Product: 6309100000.0, Product and Service, Other: 702600000.0 |
| Period | Value |
|---|---|
| FY2025 | Rest Of World: 507500000.0, UNITED STATES: 4384700000.0 |